ClinicalTrials.gg
RecruitingNCT06608875StimuLOOP-PDUpdated Oct 1, 2024

Precision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops

An interventional study of Hyper-personalized feedback (HPF intervention) and Targeted auditory stimulation during sleep (TASS verum intervention) in Parkinson Disease, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by University of Zurich · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.

Planned enrollment
25th of 67
40 · median 30
Started
2024
with 8 others
No phase
49 of 85
23 open now
Primary completion
2026-12
later than 12 of 33 live
Registered
68th of 85
by date
Lead sponsor
8 of 85
University of Zurich

Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 25th largest by planned enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2024, is one of 49 with no phase, reaches primary completion later than 12 of the 33 other live ones, and was the 68th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Parkinson Disease with a site in Switzerland, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is a neurodegenerative disease that affects about 1% of the elderly population and accounts for substantial disability and health care costs.

Disability is largely driven by mobility deficits caused by impaired gait. Effective treatments are available to restore lower limb function and improve gait, but response to treatment varies greatly from patient to patient and often shows only small effect sizes. Addressing this heterogeneity requires personalization, a concept referred to precision neurorehabilitation.

StimuLOOP.PD intends to foster structured and reproducible methods for precision neurorehabilitation of gait in PD. The investigator will conduct a proof-of-concept study to investigate a combination of two methods that are each tailored to the individual patient. Two innovative technologies are applied in concert to enhance recovery of lower limb function.

  1. Hyper-personalized feedback (HPF): For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant. This results in a two-step personalization; in a first step, the investigator will choose what movement aspect is therapeutically targeted, and in a second step, the investigator will define how the feedback is presented to the participant.
  2. Targeted auditory stimulation during sleep (TASS):The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands.

The HPF intervention is expected to induce rapid adaptations, which however do not persist over multiple days. To counter this, the investigator will leverage memory reactivation during sleep to enhance the consolidation of the movement patterns that are learned during HPF.

The investigator expect that these interventions will lead to greater gains in functional walking ability. Beyond demonstrating a proof-of-concept for novel methods of precision neurorehabilitation, positive results of this project may have implications for neurorehabilitation treatment in general by providing first insights into the benefits and interplay of HPF and TASS.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic Parkinson's disease with gait and postural stability deficits
  • ≥18 years of age
  • United Parkinson Disease Rating Scale (UPDRS) III gait scores 1-3
  • UPDRS III postural instability scores 1-3
  • Prescribed rehabilitation therapy at cereneo
  • as documented by signature
  • Adjustments in dopaminergic medication and deep brain stimulation (DBS) to improve motor symptoms implemented to the current best possible extent

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment, (MoCa) \< 20
  • Comprehensive aphasia precluding the understanding of study-related information
  • Other neurological or medical condition that caused sustained gait and/or postural stability deficits
  • Expected acute hospitalization during the training period
  • History of a physical or neurological condition that interferes with study procedures
  • Social and/or personal circumstances that interfere with the ability to return for therapy sessions and follow-up assessments
  • Not capable of voluntary gait adaptation
  • Patients taking benzodiazepines or Z-drugs that have a significant effect on sleep EEG
  • Recent DBS implant (≤ 6 months)
  • Inability to perform outcome assessments without walking aid
  • Skin disorders/problems/allergies in face/ear area that could worsen with electrode application (e.g. nickel allergy)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Sham comparator
    Adaptation Arm

    Hyper-personalized feedback-based motor rehabilitation with sham targeted auditory stimulation during sleep (HPF intervention, TASS sham intervention)

    Behavioral: Hyper-personalized feedback (HPF intervention) · Behavioral: Control targeted auditory stimulation during sleep (TASS sham intervention)

  • Experimental
    Consolidation arm

    Hyper-personalized feedback-based motor rehabilitation with targeted auditory stimulation during sleep (HPF intervention, TASS verum intervention)

    Behavioral: Hyper-personalized feedback (HPF intervention) · Behavioral: Targeted auditory stimulation during sleep (TASS verum intervention)

Interventions

  • BehavioralHyper-personalized feedback (HPF intervention)

    For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.

  • BehavioralTargeted auditory stimulation during sleep (TASS verum intervention)

    The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands

  • BehavioralControl targeted auditory stimulation during sleep (TASS sham intervention)

    Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)

06

What researchers measure

Primary outcomes

  1. 6 min walking test

    Change in functional walking ability assessed with the 6 min walking test

    Time frame: Pre, immediately post motor rehabilitation and 1 month post motor rehabilitation

  2. MiniBEST test

    the change in postural stability assessed with the MiniBEST test

    Time frame: Pre, immediately post motor rehabilitation and 1 month post motor rehabilitation

Secondary outcomes

  1. Phase Coordination Index

    Motor learning assessed via changes in coordination. Coordination assessed using the Phase Coordination Index.

    Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training

  2. Continuous Relative Phase

    Motor learning assessed via changes in coordination. Coordination assessed using Continous Relative Phase.

    Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training

  3. Variability

    Motor learning assessed via changes in variability. Variability assessed using the coefficient of variation (%CV) of common spatio-temporal gait parameters, including stride time, stride length, step length, swing time, stance time, step width, and double limb support time.

    Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training

  4. Symmetry

    Motor learning assessed via changes in symmetry. Symmetry (%) in step length and step time.

    Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training

  5. Margin of Stability

    Motor learning assessed via changes in stability. Stability assessed using Margin of Stability.

    Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training

  6. Resilience

    Motor learning assessed via changes in stability: Stability assessed using resilience metrics.

    Time frame: Pre, immediately post motor rehabilitation training and during 15 days of motor rehabilitation training and one-month post-training

Other outcomes

  1. Standard sleep architecture measures

    Single-channel sleep Electroencephalography (EEG): (e.g. % N3, % N2, wake after sleep onset, Sleep efficiency) from scored EEG, electromyography (EMG), and electrooculography (EOG) signal (note: bandpass filtered EMG and EOG signal will only be used for offline sleep scoring according to American Academy of Sleep Medicine standards)

    Time frame: During 15 days of motor rehabilitation training

  2. Event related spectral perturbation (ERSP)

    ERSP: \[µV\^2/Hz or % or dB of baseline if normalized over time\] and event-related potential (ERP) \[µV over time\] locked to stimuli from frontal, single-channel EEG signal

    Time frame: During 15 days of motor rehabilitation training

  3. Frequency spectrum

    Single-channel sleep EEG: \[µV\^2/Hz\] from frontal, single-channel EEG signal

    Time frame: During 15 days of motor rehabilitation training

  4. Slow-wave activity

    Single-channel sleep EEG: \[µV\^2/Hz or % or dB of baseline if normalized\] in scored non-rapid eye movement (NREM) sleep from frontal, single-channel EEG signal

    Time frame: During 15 days of motor rehabilitation training

  5. Sigma power

    Single-channel sleep EEG: \[µV\^2/Hz or % or dB of baseline if normalized\] in scored NREM sleep from frontal, single-channel EEG signal

    Time frame: During 15 days of motor rehabilitation training

  6. Quantity

    Single-channel sleep EEG: density \[number/min\], and characteristics (amplitude, peak frequency, bandwidth) of sleep oscillations (spindles, K-complexes, slow-wave-spindle-coupling) in scored NREM sleep from frontal, single-channel EEG signal.

    Time frame: During 15 days of motor rehabilitation training

  7. Quality of Life (EQ-5D-5L)

    Patient-Reported Outcomes (PRO) measurement that can assess patients' quality of life, irrespective of the disease. Quality of life scale developed by EuroQol Group called EQ-5D-5L, scoring from level 1 indicating no problem to level 5 indicating extreme problems.

    Time frame: Pre motor rehabilitation training and 1 month after training

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 31 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2024
First posted
Sep 23, 2024
StartActual
May 16, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06608875
Collaborators
ETH Zurich (Switzerland), Cereneo AG, University Children's Hospital, Zurich, Lake Lucerne Institute AG
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
May 16, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion